Alamar Biosciences, Inc. revenue by segment ALMR

Alamar Biosciences, Inc. splits its revenue into 3 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Consumables at $17.8 million, 53% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Sep 30, 2026
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Revenue
—
34
29
26
Consumables
—
18
share 53.2%
15
share 52.6%
14
share 53.6%
Instruments
—
8
share 25.2%
8
share 26.5%
7
share 28.4%
Other services
—
7
share 21.6%
6
share 20.9%
5
share 18.0%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Laboratory Analytical Instruments (SIC 3826)
Listed as
ALMR (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Fremont, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
2104204

Other Laboratory Analytical Instruments companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.